People | January 03, 2025
Abbott India appoints Prithwish K Banerji as Commercial Director - Women’s Health, Metabolics and International Business
Prithwish has close to 28 years of experience in a Commercial role
Prithwish has close to 28 years of experience in a Commercial role
Acquisition adds potential best-in-class disease-modifying therapy for Alzheimer's disease
CLL is one of the most common leukemias among adults affecting more than 200,000 people in the US
Emraclidine was well-tolerated with an adverse event profile consistent with Phase 1b trial
The company has reported total income of Rs. 1,693.15 crores during the period ended September 30, 2024
Partnership to Combine AbbVie's Oncology Expertise with EvolveImmune's Proprietary EVOLVE T-Cell Engager Platform to Develop Novel Multispecific Therapeutic Antibodies for Cancer
Strengthening focus in Alzheimer's disease and neuroscience pipeline
Teliso-V is an investigational antibody-drug conjugate (ADC) for patients with previously treated nonsquamous non-small cell lung cancer (NSCLC) with c-Met protein overexpression
The objectives of the campaign are to raise awareness about glaucoma, its risk factors, and the importance of regular eye check-up
This license will enable Abbott to enhance access to this novel therapy to more patients across India
Subscribe To Our Newsletter & Stay Updated
